The AstraZeneca (AZN) share price is high, is this FTSE 100 star a recession-beating stock?

The AstraZeneca (AZN) share price is up 42% since the March market crash but is this FTSE 100 (INDEXFTSE:UKX) riser overvalued?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Global biopharmaceutical company AstraZeneca (LSE:AZN) has done very well this year. The AZN share price is up 42% since the March stock market crash. This is because it has developed a strong portfolio of products to combat some of the world’s most prevalent diseases. This includes medicines for cancer, gastrointestinal disorders, neuroscience, cardiovascular conditions, respiratory troubles, infection and inflammation.

With the coronavirus resulting in many of these ailments, particularly infection, respiratory issues, and inflammation, the AZN share price has soared. It has enjoyed a string of positive headlines with drug trials going well and orders coming in. However, pharma is a volatile industry where trials often fail. It pumps enormous volumes of cash into research and development, and not every speculative development creates a cash cow.

Is the AZN share price overvalued?

Consumer confidence has risen in AstraZeneca because it sells vital drugs and because pharmaceuticals are a necessary purchase even in times of recession. However, the AZN share price has now reached a point that seems overvalued, compared with its profit margin and ongoing R&D costs.

A useful gauge of company value comes in the price-to-earnings ratio (P/E). It has long been a part of the value investor’s analysis of suitable stocks to buy. Benjamin Graham and Warren Buffett used it to assess a company’s intrinsic value, along with dividend yield and earnings growth.

The P/E is the ratio of a company’s share price to the company’s current or forecast earnings per share. The AZN share price is £84.45 and current earnings per share are 82p. This means the P/E is £84.45/£0.82 = 102.

To give you a sign of how this relates to value, according to the Benjamin Graham playbook, a good P/E is 10. Above 15 is likely overvalued and below 10 potentially undervalued.

With a P/E of 102, the AZN share price is clearly overvalued. Putting it in perspective — to sustain this ridiculously high P/E AstraZeneca would need to maintain a healthy growth rate of over 20% a year for at least 10 years. Even for an international pharma/biotech conglomerate, this seems an optimistic goal to me. 

Is AstraZeneca a recession-proof stock?

Fears of a global recession are mounting, and while various government grants, loans, and bailouts are so far keeping the economy afloat, this is unlikely to last. Forecasts from the Organisation for Economic Cooperation and Development show the UK economy will contract by 11.5% this year. But this could rise to 14% if a second wave of the coronavirus returns later in 2020. This does not bode well for the stock market, and I think another market crash is likely.

In March, the AZN share price fell to a low of £59. Following this, it steadily rose to breach £90. Press reports in June cited AstraZeneca had reportedly approached Gilead about a potential merger. This caused the AstraZeneca share price to fall, and it has since been faltering around the £84 mark. I think a second market crash would send it spiralling again.

There is no doubt AstraZeneca is a good, strong company and I believe it will thrive long into the future. But the AZN shares are not a bargain at today’s prices. Its dividend yield is a paltry 2.5% and I think it could well be at risk of a share price correction. There are other recession-busting FTSE 100 stocks I like the look of, including SSE.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »